Xiaofeng Yao Selected Research

Neoplasms (Cancer)

5/2024	Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma.
1/2024	Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC.
1/2023	Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not?
1/2023	The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation.
1/2022	Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer.
1/2021	Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
1/2017	Clinicopathological significance of ZEB-1 and E-cadherin proteins in patients with oral cavity squamous cell carcinoma.
1/2017	Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152.
2/2016	IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.
1/2009	Biomarkers identification and detection based on GMR sensor and sub 13 nm magnetic nanoparticles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaofeng Yao Research Topics

Disease

14	Insulin Resistance 04/2024 - 01/2016
10	Neoplasms (Cancer) 05/2024 - 01/2009
9	Squamous Cell Carcinoma of Head and Neck 05/2024 - 01/2017
8	Inflammation (Inflammations) 04/2024 - 01/2008
8	Type 2 Diabetes Mellitus (MODY) 10/2023 - 04/2016
5	Liver Cirrhosis (Hepatic Cirrhosis) 05/2024 - 03/2020
5	Non-alcoholic Fatty Liver Disease 05/2024 - 01/2018
5	Mitochondrial Diseases (Mitochondrial Disease) 12/2023 - 06/2013
3	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2017
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 06/2013
2	Lymphatic Metastasis 03/2023 - 01/2017
2	Carcinogenesis 07/2022 - 01/2019
2	Lipid Metabolism Disorders (Metabolism Disorders, Lipid) 12/2021 - 01/2019
2	Glucose Intolerance 11/2020 - 01/2019
2	Fibrosis (Cirrhosis) 03/2020 - 02/2019
2	Diabetes Mellitus 01/2019 - 02/2016
2	Hepatocellular Carcinoma (Hepatoma) 05/2018 - 01/2016
2	Atherosclerosis 08/2017 - 08/2016
1	Liver Diseases (Liver Disease) 05/2024
1	Keratitis 04/2024
1	Infections 04/2024
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2023
1	Iron Overload 03/2023
1	Papillary Thyroid Cancer 03/2023
1	Thyroiditis 03/2023
1	Adenocarcinoma 01/2023
1	Acute Kidney Injury (Acute Renal Failure) 05/2022
1	Microsatellite Instability 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2022
1	Colitis 12/2021
1	Obesity 05/2021
1	Esophageal Squamous Cell Carcinoma 01/2021
1	Idiopathic Noncirrhotic Portal Hypertension 03/2020
1	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus) 03/2020
1	Hypertension (High Blood Pressure) 03/2020
1	Keshan disease 09/2019
1	Beriberi 09/2019
1	Cardiomyopathies (Cardiomyopathy) 09/2019
1	Cardiotoxicity 09/2019

Drug/Important Bio-Agent (IBA)

20	ArsenicIBA 05/2024 - 02/2016
9	InflammasomesIBA 10/2023 - 01/2018
7	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2009
4	perfluorooctaneIBA 04/2024 - 01/2016
4	CalciumIBA 04/2024 - 01/2022
4	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2017
3	6-methyladenineIBA 05/2024 - 10/2023
3	Interleukin-6 (Interleukin 6)IBA 04/2024 - 01/2009
3	Persistent Organic PollutantsIBA 03/2023 - 01/2016
3	serum P-component (CIt)IBA 05/2022 - 08/2017
3	3-methyladenineIBA 01/2021 - 05/2018
3	Arsenic Trioxide (Trisenox)FDA Link 02/2019 - 01/2018
3	Taurine FDA Link 01/2019 - 01/2018
2	sodium arsenite (sodium metaarsenite)IBA 05/2024 - 12/2023
2	Diethylhexyl Phthalate (DEHP)IBA 12/2023 - 12/2021
2	Cetuximab (Erbitux)FDA Link 01/2023 - 01/2018
2	undecan-2-oneIBA 07/2022 - 05/2021
2	PatulinIBA 05/2022 - 05/2018
2	citreoviridinIBA 05/2022 - 09/2019
2	Adenosine Triphosphate (ATP)IBA 05/2022 - 09/2019
2	MycotoxinsIBA 05/2022 - 09/2019
2	LipidsIBA 12/2021 - 01/2018
2	Sirolimus (Rapamycin)FDA Link 05/2021 - 05/2018
2	CollagenIBA 01/2021 - 03/2020
2	acetopyrrothine (thiolutin)IBA 01/2021 - 01/2021
2	Deubiquitinating EnzymesIBA 01/2021 - 01/2021
2	Insulin (Novolin)FDA Link 11/2020 - 01/2019
2	Tacrine (Cognex)FDA Link 01/2019 - 06/2013
2	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 01/2017
2	CateninsIBA 01/2017 - 01/2017
1	statticIBA 05/2024
1	N-methyladenosineIBA 05/2024
1	Eosine Yellowish-(YS) (Eosin)IBA 04/2024
1	formononetinIBA 04/2024
1	Flavin Mononucleotide (FMN)IBA 04/2024
1	Hematoxylin (Haematoxylon)IBA 04/2024
1	Beclin-1IBA 01/2024
1	Tyrosine Kinase InhibitorsIBA 01/2024
1	phthalic acid (phthalate)IBA 12/2023
1	GW 6471IBA 12/2023
1	Protective AgentsIBA 12/2023
1	FilaminsIBA 10/2023
1	Small Interfering RNA (siRNA)IBA 10/2023
1	MethyltransferasesIBA 10/2023
1	IronIBA 03/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Annexin A1IBA 11/2022
1	rat MIRN27 microRNAIBA 07/2022
1	MicroRNAs (MicroRNA)IBA 07/2022
1	TubulinIBA 06/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2022
1	Death Domain ReceptorsIBA 01/2022
1	theanineIBA 12/2021
1	honokiolIBA 05/2021
1	Cathepsin BIBA 01/2021
1	MicronutrientsIBA 09/2019
1	chromium hexavalent ionIBA 01/2019

Therapy/Procedure

8	Therapeutics 05/2024 - 01/2017
1	Immunotherapy 01/2023
1	Immunomodulation 01/2023